BFC Planning’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.05K Hold
5,000
– – ﹤0.01% 2597
2026
Q2
$7K Hold
5,000
– – ﹤0.01% 2538
2026
Q1
$8.45K Hold
5,000
– – ﹤0.01% 2110
2025
Q4
$7.1K Hold
5,000
– – ﹤0.01% 2207
2025
Q3
$8.2K Hold
5,000
– – ﹤0.01% 2009
2025
Q2
$3.66K Hold
5,000
– – ﹤0.01% 2159
2025
Q1
$4.04K Hold
5,000
– – ﹤0.01% 2092
2024
Q4
$6.9K Hold
5,000
– – ﹤0.01% 1913
2024
Q3
$5.2K Buy
+5,000
New +$6.86K ﹤0.01% 2001

Other funds holding CHRS

BFC Planning's CHRS Position: Q3 2026 in Review

BFC Planning held its Coherus Oncology (CHRS) position steady in Q3 2026 at 5,000 shares worth $6.05K. The position accounts for ﹤0.01% of the portfolio, ranked #2597.

BFC Planning first reported a position in CHRS in Q3 2024 and has held it in 9 quarters since. The position peaked at $8.45K in Q1 2026. 100 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • BFC Planning held 5,000 shares of Coherus Oncology worth $6.05K as of Q3 2026.
  • BFC Planning left its Coherus Oncology share count unchanged in Q3 2026.
  • Coherus Oncology made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2597 holding.
  • BFC Planning first reported a position in Coherus Oncology in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Coherus Oncology position peaked at $8.45K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.